Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abbott
Abbott Study Shows Investigational Heat-Stable Norvir Tablet Provides Similar Drug Levels to Current Norvir Capsule
August 22nd, 2008
Abbott (NYSE:ABT) presented pivotal data at the XVII International AIDS Conference (AIDS 2008) in Mexico City today showing that its investigational Norvir(R) (ritonavir) tablet and the current soft-gelatin capsule provide similar levels of drug in the blood. The heat-stable Norvir tablet will not require refrigeration, making it more convenient for patients to use, particularly in developing countries where the majority of people with HIV live. "The heat-stable formulation of ritonavir may help to further expand protease inhibitor-based HAART (highly active antiretroviral therapy) in regions where the need for refrigeration of HIV medicines is a...
Source: Health Business Week (2008-08-22)
|
